Benitec Biopharma (Benitec Biopharma) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Days Sales Outstanding?

Benitec Biopharma's average Accounts Receivable for the three months ended in Dec. 2023 was $0.05 Mil. Benitec Biopharma's Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Benitec Biopharma's Days Sales Outstanding or its related term are showing as below:

BNTC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.1 Med: 134.9 Max: 341.07
Current: 341.07

During the past 11 years, Benitec Biopharma's highest Days Sales Outstanding was 341.07. The lowest was 3.10. And the median was 134.90.

BNTC's Days Sales Outstanding is ranked worse than
89.81% of 893 companies
in the Biotechnology industry
Industry Median: 72.43 vs BNTC: 341.07

Benitec Biopharma's Days Sales Outstanding declined from Dec. 2022 (231.38) to Dec. 2023 (0.00).

Benitec Biopharma Days Sales Outstanding Historical Data

The historical data trend for Benitec Biopharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Days Sales Outstanding Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Sales Outstanding

Get a 7-Day Free Trial

3.10

222.01

259.83

70.00

141.13

Benitec Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															231.38	104.77	723.48	-	-

Competitive Comparison of Benitec Biopharma's Days Sales Outstanding

For the Biotechnology subindustry, Benitec Biopharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benitec Biopharma's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Days Sales Outstanding falls into.

Benitec Biopharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Benitec Biopharma's Days Sales Outstanding for the fiscal year that ended in Jun. 2023 is calculated as

	Days Sales Outstanding (A: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (0.003	+	0.055)	/	2 )	/	0.075	*	365
=	0.029					/	0.075	*	365
=	141.13

Benitec Biopharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.053	+	0.053)	/	2 )	/	0	*	365 / 4
=	0.053					/	0	*	365 / 4
=	N/A

Benitec Biopharma (NAS:BNTC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Benitec Biopharma Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Benitec Biopharma (Benitec Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Executives

J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Megan Boston	director, officer: Executive Director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira	10 percent owner	18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith	director	C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis	director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks	director, officer: Chief Executive Officer	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000